BCL2

Apoptosis regulator Bcl-2

124,362 patent compounds predicted against BCL2, 92,293 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gossypol (SCHEMBL3939)	1.00	11/20
SCHEMBL206442	0.55	11/20
Abt 737 (SCHEMBL158942)	1.00	9/20
Abt 737 (SCHEMBL170470)	1.00	9/20
SCHEMBL158040	1.00	8/20
SCHEMBL158041	1.00	8/20
SCHEMBL161869	0.63	8/20
SCHEMBL214415	0.41	8/20
SCHEMBL78583	0.55	7/20
SCHEMBL78662	0.55	7/20
SCHEMBL110590	0.42	6/20
SCHEMBL1345	0.41	6/20
SCHEMBL219876	0.48	5/20
Hydrochloric Acid (SCHEMBL219199)	0.48	5/20
Athraquinones A (SCHEMBL18614)	1.00	4/20
Epigalocatechin Gallate (SCHEMBL35258)	1.00	4/20
Epicatechin Gallate (SCHEMBL39046)	1.00	4/20
Epicatechin Gallate (SCHEMBL39047)	1.00	4/20
Gallocatechin Gallate (SCHEMBL49461)	1.00	4/20
Catechin Gallate (SCHEMBL145289)	1.00	4/20

Germline variants in BCL2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BCL2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BCL2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma	PHASE4	UNKNOWN
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)	PHASE3	UNKNOWN
A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)	PHASE2/PHASE3	COMPLETED
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia	PHASE3	COMPLETED
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL	PHASE2	RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma	PHASE2	RECRUITING
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	PHASE2	COMPLETED
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML	PHASE2	ACTIVE_NOT_RECRUITING
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer	PHASE2	COMPLETED
Ibrutinib + Venetoclax in Untreated WM	PHASE2	ACTIVE_NOT_RECRUITING
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	PHASE2	COMPLETED
ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia	PHASE2	COMPLETED
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission	PHASE2	ACTIVE_NOT_RECRUITING
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	PHASE1	ACTIVE_NOT_RECRUITING
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	PHASE1	COMPLETED
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	PHASE1	COMPLETED
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects	PHASE1	COMPLETED
Safe Accelerated Venetoclax Escalation in CLL	PHASE1	ACTIVE_NOT_RECRUITING
Smoking Influence on Apoptosis in Periodontitis	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.	nan	RECRUITING
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer	nan	COMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia	nan	COMPLETED
The Effect of TRA-8 on Ovarian Cancer Tissue	nan	COMPLETED
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BCL2 binder may also engage these)

Protein	Name	Similarity
O02718	—	1.000	O02718 →
P10417	—	1.000	P10417 →
Q6R755	—	0.999	Q6R755 →
P49950	—	0.999	P49950 →
Q9JJV8	—	0.998	Q9JJV8 →
Q00709	—	0.994	Q00709 →
BAK1	Bcl-2 homologous antagonist/killer	0.974	landscape →
Q5SNT2	—	0.972	Q5SNT2 →
P12755	—	0.972	P12755 →
P85299	—	0.969	P85299 →
Q8BXL9	—	0.969	Q8BXL9 →
Q9TUG2	—	0.969	Q9TUG2 →
Q812A5	—	0.969	Q812A5 →
Q2KJ58	—	0.968	Q2KJ58 →
Q5FVG6	—	0.968	Q5FVG6 →
Q80U62	—	0.968	Q80U62 →
A2SXS5	—	0.967	A2SXS5 →
A2A8U2	—	0.967	A2A8U2 →
Q8VDV3	—	0.967	Q8VDV3 →
Q0D2I5	—	0.967	Q0D2I5 →
Q6DVA0	—	0.967	Q6DVA0 →
Q8CC12	—	0.966	Q8CC12 →
Q60698	—	0.966	Q60698 →
Q8C190	—	0.966	Q8C190 →
ABHD16A	Phosphatidylserine lipase ABHD16A	0.966	landscape →
Q9NUG4	—	0.966	Q9NUG4 →
A4D2P6	—	0.966	A4D2P6 →
NIBAN2	Protein Niban 2	0.965	landscape →
Q6NS60	—	0.965	Q6NS60 →
Q96CX2	—	0.965	Q96CX2 →